Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders

Nephrology

Volumn 9, Issue 6, 2004, Pages 406-413

  Sturtevant, Joanna M ^a   Hawley, Carmel M ^a   Reiger, Kylie ^a   Johnson, David W ^a   Campbell, Scott B ^a   Burke, John R ^a   Bofinger, Andrew ^a   Isbel, Nicole M ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Calcium; Calcium x phosphate product; Dialysis; Parathyroid hormone; Phosphate; Sevelamer hydrochloride

Indexed keywords

CALCIUM; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLATULENCE; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; INDIGESTION; LIPOPROTEIN BLOOD LEVEL; MALE; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; TITRIMETRY;

ALUMINUM HYDROXIDE; CALCIUM; CALCIUM CARBONATE; DRUG THERAPY, COMBINATION; EPOXY COMPOUNDS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPIDS; MAGNESIUM SILICATES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PHOSPHORUS METABOLISM DISORDERS; POLYAMINES; POLYETHYLENES; RENAL DIALYSIS;

EID: 12244310195     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2004.00338.x     Document Type: Article

References (20)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 1998; 31: 607-17.
2. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am. J. Kidney Dis. 2000; 35: 1226-37.
3. Llach F. Calcific uremic arteriolopathy (calciphylaxis): an evolving entity? Am. J. Kidney Dis. 1998; 32: 514-18.
4. Plone MA, Petersen JS, Rosenbaum DP, Burke SK. Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin. Pharmacokinet. 2002; 41: 517-23.
5. Wilkes BM, Reiner D, Kern M, Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin. Nephrol. 1998; 50: 381-6.
6. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999; 55: 299-307.
7. Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv. Ren. Replace. Ther. 2003; 10: 133-45.
8. Chertow GM, Burke SK, Lazarus JM et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am. J. Kidney Dis. 1997; 29: 66-71.
9. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium X phosphate product and lipid profile of haemodialysis patients. Nephrol. Dial. Transplant. 1999; 14: 2907-14.
10. Sadek T, Mazouz H, Bahloul H et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol. Dial. Transplant. 2003; 18: 582-8.
11. Bleyer AJ, Burke SK, Dillon M et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. 1999; 33: 694-701.
12. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-52.
13. Hergesell O, Ritz E. Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol. Dial. Transplant. 2002; 17: 14-17.
14. Cizman B. Hyperphosphataemia and treatment with sevelamer in haemodialysis patients. Nephrol. Dial. Transplant. 2003; 18 (Suppl. 5): v47-9.
15. McIntyre CW, Patel V, Taylor GS, Fluck RJ. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol. Dial. Transplant. 2002; 17: 1643-8.
16. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44: 1049-60.
17. Borras M, Marco MP, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. Perit. Dial. Int. 2002; 22: 737-8.
18. Marco MP, Muray S, Betriu A et al. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 2002; 92: 499-500.
19. Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder. Kidney Int. 2000; 57: 1776-7.
20. Collins AJ, St Peter WL, Dalleska FW, Ebben JP, Ma JZ. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin. Nephrol. 2000; 54: 334-41.